Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-03 08:00 |
Biophytis annonce le Lancement de son Offre Publique en vue d’une Introduction …
|
French | 140.3 KB | ||
| 2021-01-20 08:00 |
Biophytis annonce le dépôt public d’un document d’enregistrement en vue d’une I…
|
French | 239.1 KB | ||
| 2021-01-19 08:01 |
Biophytis annonce son projet de déposer publiquement plus tard dans la journée …
|
French | 160.3 KB | ||
| 2021-01-19 08:01 |
Biophytis Announces Plan to Publicly File Later Today Registration Statement fo…
|
English | 199.2 KB | ||
| 2021-01-19 08:00 |
Biophytis reçoit la recommandation du DMC pour commencer le recrutement de la P…
|
French | 455.6 KB | ||
| 2021-01-19 08:00 |
BIOPHYTIS receives DMC recommendation for starting recruitment for Part 2 of it…
|
English | 550.9 KB | ||
| 2021-01-07 08:00 |
Biophytis to Participate in Upcoming Investor and Partnering Conferences During…
|
English | 129.5 KB | ||
| 2021-01-07 08:00 |
Biophytis annonce sa participation à plusieurs conférences pendant la semaine J…
|
French | 132.8 KB | ||
| 2020-12-16 08:00 |
Biophytis – Last patient completes final visit in SARA-INT, a Phase 2 clinical …
|
English | 158.0 KB | ||
| 2020-12-16 08:00 |
Biophytis – Sortie du dernier patient de l’étude SARA-INT de phase 2, évaluant …
|
French | 165.2 KB | ||
| 2020-12-14 08:00 |
Biophytis Presents SARA-OBS study results at the Annual Conference of The Socie…
|
English | 179.5 KB | ||
| 2020-12-14 08:00 |
Biophytis présente les résultats de l’étude SARA-OBS au Congrès annuel sur la S…
|
French | 182.3 KB | ||
| 2020-12-11 08:00 |
Biophytis - First Patient Enrolled in France in COVA, an International Phase 2/…
|
English | 197.8 KB | ||
| 2020-12-11 08:00 |
Biophytis - Inclusion du premier patient en France dans COVA, un essai clinique…
|
French | 191.3 KB | ||
| 2020-12-03 08:00 |
Biophytis - Prochaines étapes créatrices de valeur potentielle
|
French | 227.3 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
